Global incidence and mortality rates in pancreatic cancer and the association with the Human Development Index: decomposition approach

Veisani, Yousef; Jenabi, Ensiyeh; Khazaei, Salman; Nematollahi, Shahrzad

doi:10.1016/j.puhe.2017.12.015

Cited by 38 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of skin cancers is increasing worldwide, as a result of the chronic exposure to sunlight, climatic changes and individual and social conditions [ 1 , 2 ]. As a whole, skin cancers include cutaneous melanoma (CM) and non-melanoma skin cancer (NMSC) that are mainly represented by basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).…”

Section: Introductionmentioning

confidence: 99%

Non-Melanoma Skin Cancers: Biological and Clinical Features

Cives

Mannavola

Lospalluti

et al. 2020

IJMS

115

View full text Add to dashboard Cite

Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in their clinical presentation, as well as in their biological evolution. While the deregulation of the Hedgehog pathway is commonly observed in BCC, SCC and MCC are characterized by a strikingly elevated mutational and neoantigen burden. As result of our improved understanding of the biology of non-melanoma skin cancers, innovative treatment options including inhibitors of the Hedgehog pathway and immunotherapeutic agents have been recently investigated against these malignancies, leading to their approval by regulatory authorities. Herein, we review the most relevant biological and clinical features of NMSC, focusing on innovative treatment approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Non-Melanoma Skin Cancers: Biological and Clinical Features

Cives

Mannavola

Lospalluti

et al. 2020

IJMS

115

View full text Add to dashboard Cite

show abstract

“…The 5-year survival rate of pancreatic cancer patients is less than 5% and most of the patients are diagnosed at a very advanced stage owing to its asymptomatic characteristic 1. According to the worldwide statistic in 2012, it is estimated 338,000 new cases are diagnosed every year and the annual mortality rate is close to the incidence rate with 331,000 death cases reported 2. To date, the best potential treatment for non-metastasized patients is pancreatectomy, yet only 15–20% of patients are suitable for surgical resection and more than 65% of patients undergoing surgery show disease recurrence 3.…”

Section: Introductionmentioning

confidence: 99%

<p>SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling</p>

Gao

Chen

Cheng

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: Accumulating studies have reported that aberrant expression of SLC5A1 is a negative prognostic factor to various cancer patients. Purpose: Pancreatic cancer tissue has also shown to harbor higher expression of SLC5A1, however how SLC5A1 mediates pancreatic cancer cells growth remains unclear. Methods: In this study, we examined the mRNA and protein expressions of SLC5A1 in human pancreatic tissue and various cell lines. The in vitro and in vivo roles of SLC5A1 in pancreatic cancer were investigated through stably transfected pancreatic cells with shRNA plasmid targeting SLC5A1. Results: Our results observed SLC5A1 was over-expressed in human pancreatic cancer tissues as well as most pancreatic cancer cell lines. Both in vitro and in vivo inhibition of SLC5A1 retarded pancreatic cancer cell growth and progression. The SLC5A1 knockdown mediated growth suppression is mainly regulated by reduced cellular glucose uptake by pancreatic cancer cells. Our further mechanistic observation showed that inhibition of SLC5A1 induced AMPK-dependent mTOR suppression and pharmacological inhibition of AMPK rescued the effect of SLC5A1 blockade. Further protein-protein interaction analysis showed association of SLC5A1 with EGFR and knockdown of EGFR also showed decreased cellular survival and glucose uptake by pancreatic cancer cells. Conclusion: Our findings postulated SLC5A1/EGFR as the potential therapeutic target of pancreatic cancer patients.

show abstract

“…People in countries with higher HDI have better life expectancy; pancreatic cancer being more common in the older age group, incidence of pancreatic cancer is higher in countries with high HDI as shown by Wong et al (2) (Figure 1). Over the last two decades there has been a substantial reduction in poverty, changes in life-style, improved healthcare literacy in Asian countries leading to improving life expectancy (3). Reporting of health care data has improved as well.…”

Section: Introductionmentioning

confidence: 99%

Global trends in pancreas cancer among Asia-Pacific population

Ranganath¹,

Chu²

2021

J Gastrointest Oncol

View full text Add to dashboard Cite

The incidence of pancreatic cancer is rising. Understanding trends of pancreatic cancer is crucial prior to putting policies and interventions in place. Countries with a high human development index (HDI) have a higher incidence, prevalence and mortality due to pancreatic cancer. This global trend is replicated in the Asia-Pacific countries with high HDI having higher incidence, prevalence and mortality due to pancreatic cancer. The incidence of pancreatic cancer is rising in the Asia-Pacific population as life expectancy increases with a rising HDI. Lack of good cancer registries has resulted in under reporting of pancreatic cancer in developing countries in the Asia-Pacific region. The mortality still remains high as in the Western world as most pancreatic cancers are diagnosed in an advanced stage of the disease due to non-availability of costeffective screening tools with few patients receiving definitive care. Smoking, alcohol consumption, poor diet and obesity are significant modifiable risk factors contributing to the development of pancreatic cancer. Population based screening for pancreatic cancer is not cost-effective. Identification of hereditary and genetic factors in the Asia-Pacific population can help in targeted screening of high-risk individuals. Policies and interventions aimed at primary prevention have the greatest potential to be cost-effective yet impactful and reduce the disease burden.

show abstract

Global incidence and mortality rates in pancreatic cancer and the association with the Human Development Index: decomposition approach

Cited by 38 publications

References 13 publications

Non-Melanoma Skin Cancers: Biological and Clinical Features

Non-Melanoma Skin Cancers: Biological and Clinical Features

<p>SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling</p>

Global trends in pancreas cancer among Asia-Pacific population

Contact Info

Product

Resources

About